MedDataX Logo

To Demonstrate the Relative Bioavailability of Fluoxetine Hydrochloride Capsules, 40 mg

NCT ID: NCT00947076

Last Updated: 2017-03-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-02-28

Study Completion Date

2001-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To demonstrate the relative bioavailability of fluoxetine hydrochloride capsules, 40 mg.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

To Demonstrate the Relative Bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Healthy Adult Males Under Fasting Conditions

NCT00913718

Depression
COMPLETED PHASE1

To Demonstrate the Relative Bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Healthy Adult Males Under Fed and Fasted Conditions

NCT00913588

Depression
COMPLETED PHASE1

90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions

NCT01247272

Healthy
COMPLETED PHASE1

90 mg Fluoxetine Hydrochloride Capsules Under Non-Fasting Conditions

NCT01247285

Healthy
COMPLETED PHASE1

A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term Dosing

NCT01808612

Major Depressive Disorder
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc)

Group Type EXPERIMENTAL

Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc)

Intervention Type DRUG

2

Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)

Group Type ACTIVE_COMPARATOR

Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc)

Intervention Type DRUG

Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria

* Positive test results for HIV or hepatitis B or C.
* Treatment for drug or alcohol dependence.
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sandoz

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sandoz Inc.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ronald Goldwater, M.D.

Role: PRINCIPAL_INVESTIGATOR

PharmaKinetics Laboratories Inc.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

005-49-11634

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers
NCT02366364 COMPLETED PHASE1
A Study Comparing the Drug Exposure in Humans After Administration of a 50 mg Tablet of Sertraline Hydrochloride as Compared to a 50 mg Capsule of Sertraline Hydrochloride Under Fasted (Nonfed) Conditions
NCT01235195 COMPLETED PHASE1
To Demonstrate the Relative Bioavailability of Bupropion HCI 100 mg Tablets Under Fasting Conditions
NCT00883155 COMPLETED PHASE1
A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.
NCT01243957 COMPLETED PHASE1
Drug Use Investigation for PAXIL Tablet
NCT01371435 COMPLETED
A Study of Fluoxetine in Major Depressive Disorder (MDD) Long-Term Dosing
NCT01808651 COMPLETED PHASE3
Food and Relative Bioavailability Study
NCT00843011 COMPLETED PHASE1
Antidepressant Drug Exposure and Risk of Suicide Attempt Resulting in Medical Intervention in US Adults
NCT00763724 COMPLETED
Bioavailability of Duloxetine 60 mg With Regards to Reference Product in Fasting Conditions
NCT04723238 COMPLETED PHASE1
A Study of RO4917523 in Patients With Treatment Resistant Depression
NCT00809562 COMPLETED PHASE2
Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder
NCT01447576 COMPLETED PHASE2
MDD POC Study GSK372475 Subjects Depressive Disease
NCT00420641 COMPLETED PHASE2
Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®
NCT03357796 COMPLETED PHASE1
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
NCT00057213 COMPLETED PHASE2
An 8 Week Study Of Adults Diagnosed With Major Depressive Disorder
NCT00057226 COMPLETED PHASE2
Study of Fluoxetine in Patients With Depersonalization Disorder
NCT00004446 COMPLETED NA
Fecal Microbiota Transplantation in Depression
NCT03281044 TERMINATED PHASE2
Switching to Duloxetine in Patients With Depression
NCT00696774 COMPLETED PHASE4
Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder
NCT01052077 COMPLETED PHASE2
A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine in Premenstrual Dysphoria
NCT00516113 COMPLETED PHASE4
Rapid Antidepressant Effects of ATP and Phosphocreatine
NCT03138681 UNKNOWN PHASE2
Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo
NCT04221230 COMPLETED PHASE2
Special Drug Use Investigation for PAXIL Tablet (20mg-Clinical Symptom Progression)
NCT01371461 COMPLETED
Prozac Treatment of Major Depression: Discontinuation Study
NCT00427128 COMPLETED PHASE4
To Demonstrate the Relative Bioavailability of Desipramine Hydrochloride 50 mg Tablets
NCT00913237 COMPLETED PHASE1